Tag: Lexicon

Big Apple NETs 0

December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

November 6, 2015

Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple

READ MORE
Big Apple NETs 0

September Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!

August 16, 2015

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs

READ MORE
big apple nyc 2

Luncheon with Carcinoid and Neuroendocrine Tumor Experts in New York City

November 13, 2014

The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Lunch with the Experts on Sunday, December 14, 2014 at 12:30 pm in a private dining room at Dorrian’s restaurant

READ MORE
lexicon telestar 2

Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome

August 20, 2014

Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…

READ MORE
telotristat etiprate clinical trial

Discover Something New in Carcinoid Syndrome

November 11, 2013

For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…

READ MORE
pablo lapuerta md

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

December 4, 2012

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

READ MORE
novartis oncology logo1

Carcinoid Cancer Foundation Thanks Symposium Sponsors

April 21, 2011

There’s still time to register for the Carcinoid Cancer Foundation’s 14th annual  symposium for patients, family, friends, and healthcare professionals, which will be held on Sunday, May 1st at Mount Sinai Medical Center in New York City.  The Foundation…

READ MORE